Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US pharmaceutical firm Biopure has received regulatory authorization in the UK to initiate a phase II clinical trial of its investigational oxygen therapeutic, Hemopure, as a potential cardio-protective agent in patients undergoing coronary artery bypass surgery.
Subscribe to our email newsletter
This trial is in addition to two other recently-announced non-US trials of the product, in ischemia applications, that have received regulatory clearance to proceed.
The UK Medicines and Healthcare products Regulatory Authority (MHRA) approved the protocol for a non-randomized, multi-center, prospective registry of patients undergoing multi-vessel coronary artery bypass graft (CABG) surgery. The trial is designed to assess the product’s safety and feasibility in reducing heart damage, as measured by cardiac enzyme (CK-MB) elevation, and enhancing tissue preservation during cardiopulmonary bypass.
Secondary endpoints include measurements of major adverse cardiac events, kidney function, transfusion requirements, cognitive impairment and length of hospital stay.
In the trial, a total of 60 patients will be consecutively enrolled in two groups to receive either standard-of-care treatment or intravenous administration of Hemopure (hemoglobin glutamer – 250 (bovine)) prior to cardiopulmonary bypass. Patients will be monitored until hospital discharge or six days, whichever occurs first, with a follow-up assessment at 30 days post-surgery. An independent data safety monitoring committee will monitor safety throughout the study period.